A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2025

Conditions

Healthy Volunteer

Interventions

DRUG

ABBV-382

Subcutaneous (SC) Injection

DRUG

ABBV-382

Intravenous (IV) Infusion

DRUG

Placebo for ABBV-382

IV Infusion

DRUG

Placebo for ABBV-382

SC Injection

Trial Locations (1)

Shanghai Xuhui Central Hospital /ID# 264785, Shanghai